A High-Fat Diet Increases Activation of the Glucagon-Like Peptide-1-Producing Neurons in the Nucleus Tractus Solitarii: an Effect that is Partially Reversed by Drugs Normalizing Glycemia

Glucagon-like peptide-1 (GLP-1) is a peripheral incretin and centrally active peptide produced in the intestine and nucleus tractus solitarii (NTS), respectively. GLP-1 not only regulates metabolism but also improves cognition and is neuroprotective. While intestinal GLP-1-producing cells have been well characterized, less is known about GLP-1-producing neurons in NTS. We hypothesized that obesity-induced type 2 diabetes (T2D) impairs the function of NTS GLP-1-producing neurons and glycemia normalization counteracts this effect. We used immunohistochemistry/quantitative microscopy to investigate the number, potential atrophy, and activation (cFos-expression based) of NTS GLP-1-producing neurons, in non-diabetic versus obese/T2D mice (after 12 months of high-fat diet). NTS neuroinflammation was also assessed. The same parameters were quantified in obese/T2D mice treated from month 9 to 12 with two unrelated anti-hyperglycemic drugs: the dipeptidyl peptidase-4 inhibitor linagliptin and the sulfonylurea glimepiride. We show no effect of T2D on the number and volume but increased activation of NTS GLP-1-producing neurons. This effect was partially normalized by both anti-diabetic treatments, concurrent with decreased neuroinflammation. Increased activation of NTS GLP-1-producing neurons could represent an aberrant metabolic demand in T2D/obesity, attenuated by glycemia normalization. Whether this effect represents a pathophysiological process preceding GLP-1 signaling impairment in the CNS, remains to be investigated. Supplementary Information The online version contains supplementary material available at 10.1007/s10571-021-01079-2.


Introduction
Glucagon-like peptide-1 (GLP-1) is a peptide produced in the intestine and in nucleus tractus solitarii (NTS) in the brainstem (Muller et al. 2019). GLP-1 binds to its receptor (GLP-1R) and its effects on target tissues [i.e., pancreas and central nervous system (CNS)], include improvement of glucose tolerance induction of satiety/inhibition of food intake, gastric emptying (Drucker 2018), neuroprotective actions (Darsalia et al. 2017;Gault and Holscher 2018), and modulatory effects on learning and memory (During et al. 2003).
Peripheral GLP-1 and GLP-1R agonists (GLP-1RA) used in the treatment of type 2 diabetes (T2D) to regulate hyperglycemia, readily diffuses across the blood-brain barrier (BBB) in animal models (Hunter and Holscher 2012), exerting positive effects on insulin secretion and glucose tolerance, at least in part, through CNS GLP-1R activation (Larsen et al. 1997). However, extensive transfer of GLP-1RA across the BBB in rodents is debated and indicated to 1 3 be minimal in humans with T2D (Christensen et al. 2015). Furthermore, rapid degradation of GLP-1 at the N-terminal end by dipeptidyl peptidase-4 (DPP-4) (Kieffer and Francis Habener 1999) renders it unlikely that significant amounts of active, gut-derived GLP-1 reach the CNS.
Located in NTS, GLP-1-producing neurons that project to various regions of the brain (Llewellyn-Smith et al. 2011;Larsen et al. 1997) expressing the GLP-1R (Graham et al. 2020;Merchenthaler et al. 1999;Cork et al. 2015) are surfacing as important regulators of both peripheral and central GLP-1-mediated effects. Interestingly, in relation to central GLP-1-mediated effect of GLP-1, Holt and colleagues have recently reported that NTS-produced GLP-1 can specifically modulate a satiation/satiety circuit under stress conditions and after large meals (Holt et al. 2019). Consequently, there is an increased need to better understand the role of these cells under physiological and pathophysiological conditions such as T2D.
The aim of this study was to compare the effects of a standard "healthy" diet versus an "unhealthy" obesogenic diet inducing T2D, on the function of GLP-1-producing neurons in NTS. The used obesogenic diet included highfat content but also differed from the standard diet in terms of composition and amount of energy coming from other energy sources. Specifically, we investigated whether this obesogenic diet inducing T2D could affect the number, induce atrophy, and/or induce changes in neuronal activation of GLP-1-producing neurons. We also investigated whether sustained glycemia normalization could counteract such effects.

Animal Model and Experimental Design
In accordance with the guidelines aiming to improve the ethical use of animals in experimental research (3R principle) (Balls 2009), the material (brain and plasma) came from the same mice cohort as recently used for another study. Therefore, part of the metabolic data has already been published (Lietzau et al. 2020).
Twenty-five, male C57Bl/6J mice (Charles River, Germany) were housed under controlled conditions, with ad libitum access to food and water. All applicable international, national, and institutional guidelines for the care/use of animals were followed. All experimental procedures were in accordance with the ethical standards of the Karolinska Institutet (Ethical Approval No. S7-13).
Two-month-old mice were randomly assigned to 4 experimental groups. The potential effect of obesity-induced T2D on GLP-1-producing neurons and neuroinflammation in the NTS was determined by comparing outcome parameters in mice fed an obesogenic diet enriched in fat (high-fat diet (HFD): 54% calories from fat, ssniff® E15126-34, Germany) (n=6) for 12 months with age-matched mice fed a standard diet (ENVIGO 2018, Italy; SD) (n=7). The potential effect of sustained glycemia normalization was determined by adding two groups: HFD-fed mice administered (in food) with either linagliptin (average dose of 5-7 mg/kg b.w. per day; HFD-Lina) (n=6) or glimepiride (average dose of 2-4 mg/kg b.w. per day; HFD-Gli) (n=6) for 3 months before sacrifice (between month 9 and 12). Both drugs are clinically prescribed for the treatment of T2D, but they have different mechanisms of action. Linagliptin is a dipeptidyl peptidase-4 inhibitor (DPP-4i) that prevents degradation of endogenous GLP-1, which results in increased insulin secretion/sensitivity (Deacon and Holst 2013). Additionally, DPP-4i also have neuroprotective action (reviewed in Darsalia et al. 2019;Chalichem et al. 2017). Sulfonylureas, such as glimepiride, induce direct pancreatic insulin secretion (Khunti et al. 2018). We hypothesized that an effect induced in NTS by both drugs would suggest that it is related with glycemia regulation, but induced only by linagliptin would suggest another, glycemia-independent mechanism.

Body Weight, Glycemia, DPP-4i Activity, and GLP-1 Levels
Body weight and fasting blood glucose were measured in all mice. Plasma DPP-4 enzyme activity and total active GLP-1 levels were determined (fed state) by EIA and ELISA, respectively (MesoScale Discovery, USA).

Immunohistochemistry and Quantitative Microscopy
An immunofluorescence staining protocol to quantify GLP-1-producing neurons was applied (Supplementary file) using a NewCast system (Visiopharm, Denmark), connected to Olympus BXS51 microscope (Olympus, Japan). Activation of GLP-1-producing neurons was assessed by quantifying GLP-1/cFos+ cells (Rinaman 1999). To evaluate potential atrophy, mean volume of GLP-1/cFos+ cells was measured using the nucleator technique (Gundersen et al. 1988). Potential activation of neuroinflammation in the NTS was quantified as density/mean volume of Iba-1+ microglia cells and total number of CD68+ microglia cells. Morphological analyses were performed by a blinded experimenter.

Statistical Analysis
Data were checked by the Shapiro-Wilk normality test. All studied parameters were analyzed as follows: 1 3 (1) SD versus HFD group comparisons were performed using unpaired, two-tailed t test with Welch's correction.
(2) HFD versus HFD-Lina versus HFD-Gli comparisons were performed using ordinary one-way ANOVA followed by uncorrected Fisher's LSD test.
Data are expressed as mean ± SD. p < 0.05 were considered statistically significant. All data were analyzed by GraphPad Prism 8 (USA).

Results
Twelve months of HFD intake increased body weight compared to SD-fed mice (p=0.0055) (Fig. 1a). Neither 3-month treatment with linagliptin nor glimepiride had any effect on the body weight (Fig. 1a). HFD feeding also resulted in fasting hyperglycemia (p < 0.0001 compared to the SD), normalized by both anti-diabetic drugs (p < 0.0001 compared to HFD-Lina and HFD-Gli) (Fig. 1b). In linagliptin-treated mice, the plasma activity of DPP-4 enzyme was, as expected, decreased compared to both the HFD and HFD-glimepiride groups (p < 0.0001 for both comparisons) (Fig. 1c). Furthermore, linagliptin-treated mice showed a higher concentration of active GLP-1 compared to HFD (p < 0.0157) and a similar trend, although not statistically significant (p=0.1234), was observed in comparison to the HFD-Gli group (Fig. 1d). Neither difference in DPP-4 enzymatic activity nor GLP-1 plasma concentration was detected between the HFD and HFD-Gli mice (p=0.2431 and p=0.5973, respectively) ( Fig. 1c, d).
No difference was detected in the total number of NTS GLP-1-producing neurons between HFD-and SD-fed mice, suggesting no change in GLP-1 expression or cell death. Additionally, no effect of linagliptin or glimepiride was recorded (Fig. 2a, b). However, we observed an increased number of NTS cFos+ cells in the HFD compared to SD group (p=0.0008), suggesting an increased cellular activation in NTS, with no additional effects of the anti-diabetic drugs (Fig. 2c, d). The number of double-stained GLP-1/ cFos+ cells was increased in the HFD group (p < 0.0001 compared to the SD group) (Fig. 2e, f) indicating increased activation of GLP-1+ cells. Both linagliptin (p=0.0426) and Fig 1 HFD induces obesity and hyperglycemia. Both linagliptin and glimepiride reduce hyperglycemia with no effect on body weight. Body weight (a), plasma glucose after 10 hours of fasting (b), DPP-4 activity (c), and GLP-1 concentration (d) in SD and HFD-fed mice, and HFD-fed mice treated either with linagliptin (5-7 mg/ kg/b.w. per day) or glimepiride (2-4 mg/kg/b.w. per day) for 3 months. All data are presented as mean ± SD. Unpaired two-tailed t test with Welch's correction was used to compare SD vs. HFD group. Ordinary one-way ANOVA followed by uncorrected Fisher's LSD test was used to compare HFD vs. HFD-Lina vs. HFD-Gli groups. ¤ denotes p < 0.05, ** denotes p < 0.01, ****,¤¤¤¤,&&&& denote p < 0.0001, n= 4-7. DPP-4 dipeptidyl peptidase-4 inhibitor, Gli glimepiride, GLP-1 glucagon-like peptide-1, HFD high-fat diet, Lina linagliptin, SD standard diet 1 3 ume of GLP-1-producing neurons in the studied groups (h). All data are presented as mean ± SD. Unpaired two-tailed t test with Welch's correction was used to compare SD vs. HFD group. Ordinary oneway ANOVA followed by uncorrected Fisher's LSD test was used to compare HFD vs. HFD-Lina vs. HFD-Gli groups. ¤, & denote p < 0.05, @@ denotes p < 0.01, *** denotes p < 0.001, **** denotes p < 0.0001, n = 6-7. White dotted lines outline NTS borders. Orange rectangles indicate areas with positively stained cells. Gli glimepiride, GLP-1 glucagon-like peptide-1, HFD high-fat diet, Lina linagliptin, SD standard diet 1 3 glimepiride (p=0.0158), partially, but significantly, counteracted this effect (Fig. 2f). To examine if these effects occurred specifically in GLP-1-producing neurons, we subtracted the fraction of cFos/GLP-1+ neurons from the total number of NTS cFos+/activated cells. The effects of HFD, linagliptin, and glimepiride were lost after this subtraction (Fig. 2g), indicating that the recorded increase/decrease in the number of NTS cFos+ cells (and, thus, indirectly in their activation) induced by HFD and anti-hyperglycemic treatments, respectively, occurs specifically in GLP-1-producing neurons.
Twelve months of HFD feeding had no effect on the mean volume of activated GLP-1/cFos+ cells (Fig. 2h). However, we recorded a significant decrease in this parameter in the HFD-Gli group (p=0.0215 compared to HFD, and p=0.0037 compared to HFD-Lina), suggesting increased cell atrophy.
No significant difference in Iba+ cells density in NTS between SD-and HFD-fed mice (Fig. 3a, c), or in response to anti-hyperglycemic drugs was detected (Fig. 3b, c). Interestingly, both linagliptin and glimepiride significantly reduced the volume of NTS Iba+ cells in HFD-fed mice (p=0.0252 and p=0.0449, respectively) (Fig. 3a-d), suggesting decreased neuroinflammation. We observed no CD68+ cells in any of the studied groups (data not shown).

Discussion
We hypothesized that obesity-induced T2D obtained after 12 months of HFD feeding impairs the function of NTS GLP-1-producing neurons by altering their basal activation (i.e., not pharmacologically stimulated), GLP-1 expression, and/or by inducing cellular atrophy and inflammation. Our results do not indicate significant changes in the number of GLP-1-expressing cells or atrophy/cellular death in response to HFD. However, we detected decreased volume of NTS GLP-1-producing neurons induced by glimepiride, possibly revealing partial atrophy of these cells and perhaps impaired GLP-1 production after sulfonylurea treatment. These effects may result from sulfonylurea-induced inhibition of neuronal ATP-sensitive potassium (K ATP ) channels (Rosati et al. 1998) leading eventually to apoptosis (Zhang et al.  a, b), density (c), and mean volume (d) of Iba-1+ cells in the NTS. All data are presented as Mean ± SD. Unpaired two-tailed t test with Welch's correction was used to compare SD vs.
Interestingly, in obese/T2D mice we recorded increased cFos expression in GLP-1-producing neurons indicating an increased activation/depolarization. Although unlikely, it cannot be excluded that the increased activation of GLP-1-producing neurons is not the result of elevated food consumption in HFD-fed mice (Merchenthaler et al. 1999). Whether this finding represents a pathophysiological process, similar to β-cell hypersecretion prior to β-cell failure in T2D (Aston-Mourney et al. 2008), remains to be investigated by performing studies assessing cFos under direct pharmacological challenge. The fact that both linagliptin and glimepiride decreased obesity/T2D-induced c-Fos expression in GLP-1-producing neurons may indicate that this effect occurs via glycemia regulation, since these drugs normalize glycemia through unrelated mechanisms.
No difference in neuroinflammation between SD and HFD-fed mice was detected after 12 months in NTS, which may indicate lack of an association between changes in the basal activity of GLP-1-producing neurons induced by HFD and increased neuroinflammation Though speculative, HFD may increase neuroinflammation at earlier time points, as previously reported (Speretta et al. 2019;Butler et al. 2020). This effect could be masked at 12 months by increased neuroinflammation during the normal aging process (Cribbs et al. 2012). A decreased volume of Iba+ cells was recorded in response to linagliptin and glimepiride suggesting decreased T2D-induced NTS neuroinflammation after 12 weeks of glycemia normalization. Future studies will have to demonstrate whether decreased NTS neuroinflammation of obese/T2D mice after glycemia normalization could represent a causal factor or a consequence of the normalization of the T2D-induced activation of NTS GLP-1-producing neurons.
The preliminary findings of this short communication need to be confirmed using direct methods to assess NTS neuronal activation. Additionally, electrophysiological studies should be performed to investigate whether the changes in the activation of NTS GLP-1-producing neurons are reflected in altered GLP-1R activation/GLP-1 content in areas targeted by these cells.
In conclusion, our study provides new insights into the effects of obesity-induced T2D on NTS GLP-1-producing neurons that could lead to development of new strategies to improve GLP-1-mediated metabolic control and neuronal function in the CNS.
Author Contributions GL coordinated and performed IHC studies and stereology analyses, acquired and processed images/figures, contributed to discussion, wrote, and edited the manuscript. SN, HP, and TC performed IHC studies, analyzed the data, and edited the manuscript. VD performed in vivo studies and edited the manuscript. TK provided linagliptin and glimepiride, and edited the manuscript. LT contributed to discussion and edited the manuscript. TN provided resources, contributed to discussion, and edited the manuscript. CP and CK conceived, designed, and coordinated the research plan, contributed to discussion, and wrote the manuscript.

Declarations
Conflict of interest Work in the Patrone/Nyström's NeuroCardioMetabol group (http:// ki. se/ en/ kisos/ the-neuro cardi ometa bol-group) is supported by Boehringer Ingelheim Pharma GmbH & Co. TK is employed at Boehringer Ingelheim Pharma GmbH & Co. KG. TN has received unrestricted grants from AstraZeneca and consultancy fees from Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Merck, and Sanofi-Aventis. The other authors declare that they have no conflicts of interest.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will 1 3 need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/.